Agilent Posts 19 Percent Jump in Q1 Life Sciences Revenues Driven by LC, Mass Spec Sales
February 18, 2011
Agilent Posts 19 Percent Jump in Q1 Life Sciences Revenues Driven by LC, Mass Spec Sales
The increase in sales was driven significantly by an acceleration in the instrument replacement cycle, particularly in the case of large pharmaceutical companies, said a company official.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Agilent Posts 32 Percent Jump in Q2 Revenues, Strong LC and Mass Spec Sales
May 13, 2011 / ProteoMonitor - Agilent Expects Varian to Add $111M to Life-Sci Arm's H2 Revenue, May Be a Year for Large M&A
May 21, 2010 / ProteoMonitor - Agilent Q3 Revenues Rise 22 Percent as Mass Spec Performs 'Exceptionally Well'
August 19, 2011 / ProteoMonitor - Agilent, University of Western Australia Building Plant Protein Monitoring Database
August 17, 2011 / GenomeWeb Daily News - Hutch, Broad Teams Publish Comprehensive Methods for MS-Based Biomarker Discovery and Verification
July 29, 2011 / ProteoMonitor